Literature DB >> 21341709

Cytotoxic pentacyclic and tetracyclic aromatic sesquiterpenes from Phomopsis archeri.

Chulida Hemtasin1, Somdej Kanokmedhakul, Kwanjai Kanokmedhakul, Chariya Hahnvajanawong, Kasem Soytong, Samran Prabpai, Palangpon Kongsaeree.   

Abstract

Three new sesquiterpenes, named phomoarcherins A-C (1-3), and four known compounds, kampanol A (4), R-mevalonolactone, ergosterol, and ergosterol peroxide, were isolated from the endophytic fungus Phomopsis archeri. These structures were established on the basis of spectroscopic evidence. The structure and absolute configuration of 1 were confirmed by X-ray crystallographic analysis of its p-bromobenzoate derivative (1a). Compounds 1-4 showed cytotoxicity against five cholangiocarcinoma cell lines (0.1-19.6 μg/mL), while 1 and 2 exhibited weak cytotoxicity against the KB cell line with IC(50) values of 42.1 and 9.4 μg/mL, respectively. In addition, compound 2 showed antimalarial activity against Plasmodium falciparum with an IC(50) value of 0.79 μg/mL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21341709     DOI: 10.1021/np100632g

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  3 in total

Review 1.  Antiplasmodial natural products: an update.

Authors:  Nasir Tajuddeen; Fanie R Van Heerden
Journal:  Malar J       Date:  2019-12-05       Impact factor: 2.979

2.  Genome of Diaporthe sp. provides insights into the potential inter-phylum transfer of a fungal sesquiterpenoid biosynthetic pathway.

Authors:  Jose Guedes de Sena Filho; Maureen B Quin; Daniel J Spakowicz; Jeffrey J Shaw; Kaury Kucera; Brian Dunican; Scott A Strobel; Claudia Schmidt-Dannert
Journal:  Fungal Biol       Date:  2016-04-12

3.  Chemical Assessment and Antimicrobial and Antioxidant Activities of Endophytic Fungi Extracts Isolated from Costus spiralis (Jacq.) Roscoe (Costaceae).

Authors:  Poliana Guerino Marson Ascêncio; Sérgio Donizeti Ascêncio; Aline Aires Aguiar; Adriana Fiorini; Raphael Sanzio Pimenta
Journal:  Evid Based Complement Alternat Med       Date:  2014-12-17       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.